| |
|
| |
| News |
| |
October 30, 2007
NovaLead announces preclinical results for GALNOBAX - a small molecule diabetic wound drug. Expects clinical trial to start in first half 2008. Read more |
| |
October 30, 2007
VLife Board announces de-merger of its research division into a new company NovaLead Pharma Pvt. Ltd. The new company to proceed with new round of funding for clinical development of its pipeline. |
| |
| Events |
| |
| Will be announced on time to time |
| |
| |
|
|
| |
 |
|
|
|
NovaLead Pharma discovers and develops small molecule therapeutic agents capable of multiple mechanism of action for unmet needs and areas needing improved therapeutics.
The candidate pipeline of NovaLead has a balanced mix of new chemical entities and new indications for FDA approved drugs with an addressable market estimated at over US$ 15 billion.
With majority of indications qualifying for fast-track approval from the FDA, NovaLead candidates are expected to reach market in a span of next 2 years to 7 years subject to satisfactory clinical validation. |
|
|
